Johnson City Pharmaceutical Laboratory, Crown Laboratories, pharmaceutical laboratories.#Pharmaceutical #laboratories

Posted On Mar 14 2018 by

Our Mission We are committed to developing and providing a diverse portfolio of pharmaceutical and consumer products that improve the quality of life for our customers Our Vision Devote our passion, energy and talent to become an innovative leader in the pharmaceutical industry while enriching the lives we touch Our people are your difference. From concept through commercialization, Crown Laboratories offers expertise in liquid and semi-solid product development and contract manufacturing services. Innovative solutions for the skin. With a long-standing heritage in skin care, we are passionate about providing clinicians and consumer with innovative solutions for the skin. Be well. …


Abbott Laboratories Company Information #cadence #pharma

Posted On Jan 8 2018 by

#drug manufacturer # Abbott Laboratories Latest Drug Information Updates Troxyca ER Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) is an extended-release, abuse-deterrent. Adlyxin Adlyxin (lixisenatide) is a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist indicated. Xiidra Xiidra (lifitegrast) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the. Epclusa Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A. Byvalson Byvalson (nebivolol and valsartan) is a beta adrenergic blocker and an angiotensin II receptor blocker (ARB). Zinbryta Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing. More. Was this page helpful? Drugs.com …


GMP Pharmaceutical Analysis Laboratories #evaluate #pharma

Posted On Dec 3 2017 by

#gmp pharma # The Shale Oil and Gas Revolution has changed the energy world. Intertek has kept pace by providing crucial and timely exploration, production, quality, quantity inventory, compliance, certification, training, inspection and logistics support and expertise to an industry in radical transition. Demand for non-destructive testing (NDT) has grown and Intertek is meeting the growing market for these services. We are living a connected life, and Intertek works to ensure and optimize those connections via its testing services for the Internet of Things. The world has rules, and Intertek’s constant and continuing work in regulatory compliance brings you the …


Actavis to Buy Forest Laboratories for $25 Billion #pharma #mba

Posted On Nov 30 2017 by

#forest pharma # Actavis to Buy Forest Laboratories for $25 Billion Actavis Plc, the world’s second-largest generic-drug maker by market value, agreed to buy Forest Laboratories Inc. for about $25 billion in a deal that will transform it into a developer of brand-name drugs. The deal is a win for billionaire investor Carl Icahn, Forest’s second-largest holder who gained seats on the company’s board in 2012 and 2013, and pushed for a sale. Forest investors will get cash and stock valued at $89.48 a share, based on the Feb. 14 closing price, the companies said today in a statement. The …


GMP Pharmaceutical Analysis Laboratories #pharma #industry #trends

Posted On Nov 26 2017 by

#gmp pharma # The Shale Oil and Gas Revolution has changed the energy world. Intertek has kept pace by providing crucial and timely exploration, production, quality, quantity inventory, compliance, certification, training, inspection and logistics support and expertise to an industry in radical transition. Demand for non-destructive testing (NDT) has grown and Intertek is meeting the growing market for these services. We are living a connected life, and Intertek works to ensure and optimize those connections via its testing services for the Internet of Things. The world has rules, and Intertek’s constant and continuing work in regulatory compliance brings you the …


Forest Laboratories to Acquire Furiex Pharmaceuticals #sandoz #pharma

Posted On Nov 24 2017 by

#forrest pharma # Forest Laboratories to Acquire Furiex Pharmaceuticals Today, Forest Laboratories Inc. announced that it has entered into a definitive agreement to acquire Furiex Pharmaceuticals, Inc. for up to $1.5 billion. Under the deal, Forest Laboratories will pay $95 per share, or approximately $1.1 billion in cash, and up to $30 a share, or $360 million, in contingent value rights tied to Furiex’s lead product candidate eluxadoline for irritable bowel syndrome (IBS). Forest Laboratories also announced that it has reached an agreement to sell Furiex’s royalties on alogliptin and Priligy with Royalty Pharma AG for approximately $415 million upon …


Forest Laboratories to Acquire Furiex Pharmaceuticals #leo #pharma

Posted On Oct 4 2017 by

#forrest pharma # Forest Laboratories to Acquire Furiex Pharmaceuticals Today, Forest Laboratories Inc. announced that it has entered into a definitive agreement to acquire Furiex Pharmaceuticals, Inc. for up to $1.5 billion. Under the deal, Forest Laboratories will pay $95 per share, or approximately $1.1 billion in cash, and up to $30 a share, or $360 million, in contingent value rights tied to Furiex’s lead product candidate eluxadoline for irritable bowel syndrome (IBS). Forest Laboratories also announced that it has reached an agreement to sell Furiex’s royalties on alogliptin and Priligy with Royalty Pharma AG for approximately $415 million upon …


Actavis to Buy Forest Laboratories for $25 Billion #pharma #industries

Posted On Oct 4 2017 by

#forest pharma # Actavis to Buy Forest Laboratories for $25 Billion Actavis Plc, the world’s second-largest generic-drug maker by market value, agreed to buy Forest Laboratories Inc. for about $25 billion in a deal that will transform it into a developer of brand-name drugs. The deal is a win for billionaire investor Carl Icahn, Forest’s second-largest holder who gained seats on the company’s board in 2012 and 2013, and pushed for a sale. Forest investors will get cash and stock valued at $89.48 a share, based on the Feb. 14 closing price, the companies said today in a statement. The …


Forest Laboratories, Inc #pharmaceutical #industry #trends

Posted On Oct 4 2017 by

#forest pharma # Forest Laboratories, Inc. Latest Drug Information Updates Troxyca ER Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) is an extended-release, abuse-deterrent. Adlyxin Adlyxin (lixisenatide) is a once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist indicated. Xiidra Xiidra (lifitegrast) is a lymphocyte function-associated antigen-1 (LFA-1) antagonist indicated for the. Epclusa Epclusa (sofosbuvir and velpatasvir) is a nucleotide analog polymerase inhibitor and pan-genotypic NS5A. Byvalson Byvalson (nebivolol and valsartan) is a beta adrenergic blocker and an angiotensin II receptor blocker (ARB). Zinbryta Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody indicated for the treatment of relapsing. More. Was this page helpful? …


Forest Laboratories to Acquire Furiex Pharmaceuticals #research #pharma

Posted On Sep 6 2017 by

#forrest pharma # Forest Laboratories to Acquire Furiex Pharmaceuticals Today, Forest Laboratories Inc. announced that it has entered into a definitive agreement to acquire Furiex Pharmaceuticals, Inc. for up to $1.5 billion. Under the deal, Forest Laboratories will pay $95 per share, or approximately $1.1 billion in cash, and up to $30 a share, or $360 million, in contingent value rights tied to Furiex’s lead product candidate eluxadoline for irritable bowel syndrome (IBS). Forest Laboratories also announced that it has reached an agreement to sell Furiex’s royalties on alogliptin and Priligy with Royalty Pharma AG for approximately $415 million upon …